Lophora submits CTA Application for LPH-5 directed towards a Phase I study
Lophora interviewed by Medwatch (in Danish) https://medwatch.dk/Medicinal___Biotek/article17157459.ece
Next-generation psychedelics: should new agents skip the trip?
CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next generation psychedelics. https://www.nature.com/articles/s41587-024-02285-1